← All trials
NCT03518034
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 3, 2018
- Primary completion
- Jun 5, 2022
- Completion date
- Jun 5, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 6000
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- AbbVieLead sponsor
- AllerganCollaborator
- Endo PharmaceuticalsCollaborator
- AbbVieStudy director
- Acerus Pharmaceuticals CorporationCollaborator
- Upsher-Smith LaboratoriesCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.